Cost-effectiveness of zoledronic acid in the prevention of skeletal-related events in patients with bone metastases secondary to advanced renal cell carcinoma: Application to France, Germany, and the United Kingdom

European Journal of Health Economics

Volumn 12, Issue 6, 2011, Pages 575-588

  Botteman, M F ^a   Meijboom, M ^c   Foley, I ^a   Stephens, J M ^a   Chen, Y M ^b   Kaura, S ^b  

^a PHARMERIT INTERNATIONAL   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c PHARMERIT INTERNATIONAL   (Netherlands)

Author keywords

Bisphosphonates; Bone health; Bone metastases; Cost effectiveness; Renal cell carcinoma

Indexed keywords

PLACEBO; ZOLEDRONIC ACID;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BONE DISEASE; BONE METASTASIS; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; ECONOMIC ASPECT; FRANCE; GERMANY; GOVERNMENT; HUMAN; INTERNET; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; PATHOLOGIC FRACTURE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; SKELETAL RELATED EVENT; SPINAL CORD COMPRESSION; TREATMENT DURATION; TREATMENT OUTCOME; UNITED KINGDOM; VERTEBRA FRACTURE;

BONE AND BONES; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; CARCINOMA, RENAL CELL; COST-BENEFIT ANALYSIS; DIPHOSPHONATES; FEMALE; FINANCING, GOVERNMENT; FRANCE; GERMANY; GREAT BRITAIN; HUMANS; IMIDAZOLES; MALE; MODELS, ECONOMIC; NEOPLASM STAGING; QUALITY-ADJUSTED LIFE YEARS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX;

EID: 80455168463     PISSN: 16187598     EISSN: 16187601     Source Type: Journal    
DOI: 10.1007/s10198-010-0272-0     Document Type: Article

References (40)

1. J Zekri N Ahmed RE Coleman BW Hancock 2001 The skeletal metastatic complications of renal cell carcinoma Int. J. Oncol. 19 379 382 11445855 1:STN:280:DC%2BD3MzptFSmuw%3D%3D
2. RE Coleman 1997 Skeletal complications of malignancy Cancer 80 1588 1594 9362426 10.1002/(SICI)1097-0142(19971015)80:8+<1588::AID-CNCR9>3.0.CO;2-G 1:STN:280:DyaK1c%2Fis1Onuw%3D%3D (Pubitemid 27444031)
3. V Depuy KJ Anstrom LD Castel KA Schulman KP Weinfurt F Saad 2007 Effects of skeletal morbidities on longitudinal patient-reported outcomes and survival in patients with metastatic prostate cancer Support. Care Cancer 15 869 876 17262196 10.1007/s00520-006-0203-x (Pubitemid 47387507)
4. KP Weinfurt Y Li LD Castel F Saad JW Timbie GA Glendenning KA Schulman 2005 The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer Ann. Oncol. 16 579 584 15734776 10.1093/annonc/mdi122 1:STN:280:DC%2BD2M7kvVWmtw%3D%3D (Pubitemid 40613323)
5. TE Delea J McKiernan J Brandman J Edelsberg J Sung M Raut G Oster 2006 Impact of skeletal complications on total medical care costs among patients with bone metastases of lung cancer J. Thorac. Oncol. 1 571 576 17409919 10.1097/01243894-200607000-00012 (Pubitemid 47181406)
6. T Delea J McKiernan J Brandman J Edelsberg J Sung M Raut G Oster 2006 Retrospective study of the effect of skeletal complications on total medical care costs in patients with bone metastases of breast cancer seen in typical clinical practice J. Support. Oncol. 4 341 347 16892696 (Pubitemid 44420137)
7. Aapro, M., Abrahamsson, P.A., Body, J.J., Coleman, R.E., Colomer, R., Costa, L., Crino, L., Dirix, L., Gnant, M., Gralow, J., Hadji, P., Hortobagyi, G.N., Jonat, W., Lipton, A., Monnier, A., Paterson, A.H., Rizzoli, R., Saad, F., Thurlimann, B.: Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann. Oncol. 19, 420-432 (2008)
8. LS Rosen D Gordon S Tchekmedyian R Yanagihara V Hirsh M Krzakowski M Pawlicki SP De M Zheng G Urbanowitz D Reitsma JJ Seaman 2003 Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial-the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group J. Clin. Oncol. 21 3150 3157 12915606 10.1200/JCO.2003.04.105 1:CAS:528:DC%2BD2cXpsVWqtb0%3D (Pubitemid 46606297)
9. LS Rosen D Gordon NS Tchekmedyian R Yanagihara V Hirsh M Krzakowski M Pawlicki SP De M Zheng G Urbanowitz D Reitsma J Seaman 2004 Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial Cancer 100 2613 2621 15197804 10.1002/cncr.20308 1:CAS:528:DC%2BD2cXlsFChs7s%3D (Pubitemid 38715767)
10. A Lipton M Zheng J Seaman 2003 Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma Cancer 98 962 969 12942563 10.1002/cncr.11571 1:CAS:528:DC%2BD3sXns1Sjs74%3D (Pubitemid 37022096)
11. M Botteman V Barghout J Stephens J Hay J Brandman M Aapro 2006 Cost effectiveness of bisphosphonates in the management of breast cancer patients with bone metastases Ann. Oncol. 17 1072 1082 16670202 10.1093/annonc/mdl093 1:STN:280:DC%2BD28zotVarsg%3D%3D (Pubitemid 43985242)
12. Meijboom, M., Botteman, M., Kaura, S.: Zoledronic acid is cost effective for the prevention of skeletal-related events in patients with prostate cancer and bone metastases in France and Germany. Presented at the Annual American Urology Association Meeting, 25-30 April, 2009, Chicago, IL, USA 2009
13. Stephens, J., Kaura, S., Botteman, M.F.: Cost-effectiveness of zoledronic acid versus placebo in the management of skeletal metastases in lung cancer patients: comparison across 3 European Countries. Presented at the 45th Annual Meeting of the American Society of Clinical Oncology, May 29-June 2, 2009
14. H McKean RC Miller A Jatoi 2007 Non-traumatic vertebral fractures in patients with locally advanced esophageal cancer: a previously unreported, unrecognized problem Dis. Esophagus 20 102 106 17439592 10.1111/j.1442-2050. 2007.00645.x 1:STN:280:DC%2BD2s3jtFartw%3D%3D (Pubitemid 46562847)
15. PD Ross JW Davis RS Epstein RD Wasnich 1994 Pain and disability associated with new vertebral fractures and other spinal conditions J. Clin. Epidemiol. 47 231 239 8138833 10.1016/0895-4356(94)90004-3 1:STN:280: DyaK2c7os1yntw%3D%3D (Pubitemid 24109735)
16. CL DesHarnais K Bajwa JP Markle JW Timbie C Zacker KA Schulman 2001 A microcosting analysis of zoledronic acid and pamidronate therapy in patients with metastatic bone disease Support. Care Cancer 9 545 551 10.1007/ s005200100249 (Pubitemid 32927886)
17. D Cella JZ Li JC Cappelleri A Bushmakin C Charbonneau ST Kim I Chen RJ Motzer 2008 Quality of life in patients with metastatic renal cell carcinoma treated with sunitinib or interferon alfa: results from a phase III randomized trial J. Clin. Oncol. 26 3763 3769 18669464 10.1200/JCO.2007.13.5145 1:CAS:528:DC%2BD1cXhtVGjs7rJ
18. BE Hillner JC Weeks CE Desch TJ Smith 2000 Pamidronate in prevention of bone complications in metastatic breast cancer: a cost-effectiveness analysis J. Clin. Oncol. 18 72 79 10623695 1:CAS:528:DC%2BD3cXmtFSrsA%3D%3D (Pubitemid 30036338)
19. AA Stinnett J Mullahy 1998 Net health benefits: a new framework for the analysis of uncertainty in cost-effectiveness analysis Med. Decis. Making 18 S68 S80 9566468 10.1177/0272989X9801800209 1:STN:280:DyaK1c3is1Wiuw%3D%3D (Pubitemid 28175944)
20. BA van Hout MJ Al GS Gordon FF Rutten 1994 Costs, effects and C/E-ratios alongside a clinical trial Health Econ. 3 309 319 7827647 10.1002/hec.4730030505
21. G Dranitsaris T Hsu 1999 Cost utility analysis of prophylactic pamidronate for the prevention of skeletal related events in patients with advanced breast cancer Support. Care Cancer 7 271 279 10423054 10.1007/s005200050260 1:STN:280:DyaK1MzkvF2itQ%3D%3D (Pubitemid 29302636)
22. NL Liberato M Marchetti A Tamburlini 2000 Pamidronate in advanced breast cancer: a cost-effectiveness analysis [abstract] Eur. J. Cancer 36 S4 10.1016/S0959-8049(99)00256-7
23. CE De J Hutton P Canney JJ Body P Barrett-Lee MP Neary G Lewis 2006 Cost-effectiveness of oral ibandronate compared with intravenous (i.v.) zoledronic acid or i.v. generic pamidronate in breast cancer patients with metastatic bone disease undergoing i.v. chemotherapy Support. Care Cancer 13 975 986 (Pubitemid 41636005)
24. JR Ross Y Saunders PM Edmonds S Patel D Wonderling C Normand K Broadley 2004 A systematic review of the role of bisphosphonates in metastatic disease Health Technol. Assess. 8 1 176 14960258 1:STN:280:DC%2BD2c%2Fnt1WnsA%3D%3D
25. N Kohno K Aogi H Minami S Nakamura T Asaga Y Iino T Watanabe C Goessl Y Ohashi S Takashima 2005 Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial J. Clin. Oncol. 23 3314 3321 15738536 10.1200/JCO.2005.05.116 1:CAS:528:DC%2BD2MXlsVyiu7w%3D
26. F Saad DM Gleason R Murray S Tchekmedyian P Venner L Lacombe JL Chin JJ Vinholes JA Goas M Zheng 2004 Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer J. Natl Cancer Inst. 96 879 882 15173273 10.1093/jnci/djh141 1:CAS:528:DC%2BD2cXkvVSrurk%3D (Pubitemid 38807610)
27. Marfatia, A.A., Botteman, M., Foley, I., Brandman, J., Langer, C.: Economic value of Zoledronic Acid versus placebo in the treatment of skeletal metastases in patients with solid tumors: the case of the United Kingdom (UK). Presented at the 43rd Annual Meeting of the American Society of Clinical Oncology, 2007
28. AM Mastro CV Gay DR Welch HJ Donahue J Jewell R Mercer D DiGirolamo EM Chislock K Guttridge 2004 Breast cancer cells induce osteoblast apoptosis: a possible contributor to bone degradation J. Cell. Biochem. 91 265 276 14743387 10.1002/jcb.10746 1:CAS:528:DC%2BD2cXhsVSqur4%3D
29. S Trippoli A Messori 1998 Cost-effectiveness analyses of statistically ineffective treatments JAMA 280 1992 1993 9863846 10.1001/jama.280.23.1992-a 1:STN:280:DyaK1M%2FnvFGmsg%3D%3D (Pubitemid 28562674)
30. MW Jacobson 1997 Cost effectiveness of coronary bypass surgery versus angioplasty N. Engl. J. Med. 336 1840 1841 9190503 10.1056/NEJM199706193362519 1:STN:280:DyaK2szhtlehsQ%3D%3D (Pubitemid 27262190)
31. Hlatky, M.A.: Reply to Jacobson, M.W.: Cost effectiveness of coronary bypass surgery versus angioplasty. N. Engl. J. Med. 336, 1840-1841 (1997)
32. S Trippoli M Vaiani A Messori E Tendi 2000 Survival gain in cost-effectiveness studies J. Clin. Oncol. 18 3318 10986065 1:STN:280: DC%2BD3cvotlemug%3D%3D
33. Hillner, B.E.: Reply to Trippoli et al. 2000. J. Clin. Oncol. 18, 3318 (2000)
34. LS Rosen D Gordon M Kaminski A Howell A Belch J Mackey J Apffelstaedt MA Hussein RE Coleman DJ Reitsma BL Chen JJ Seaman 2003 Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial Cancer 98 1735 1744 14534891 10.1002/cncr.11701 1:CAS:528:DC%2BD3sXovVCrsLw%3D (Pubitemid 37238631)
35. F Saad DM Gleason R Murray S Tchekmedyian P Venner L Lacombe JL Chin JJ Vinholes JA Goas B Chen 2002 A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma J. Natl Cancer Inst. 94 1458 1468 12359855 1:CAS:528: DC%2BD38XosVans7g%3D
36. EJ Small MR Smith JJ Seaman S Petrone MO Kowalski 2003 Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer J. Clin. Oncol. 21 4277 4284 14581438 10.1200/JCO.2003.05.147 1:CAS:528:DC%2BD2cXpsVWqu7w%3D (Pubitemid 46621802)
37. RJ Motzer TE Hutson P Tomczak MD Michaelson RM Bukowski O Rixe S Oudard S Negrier C Szczylik ST Kim I Chen PW Bycott CM Baum RA Figlin 2007 Sunitinib versus interferon alfa in metastatic renal-cell carcinoma N. Engl. J. Med. 356 115 124 17215529 10.1056/NEJMoa065044 1:CAS:528:DC%2BD2sXksVGqsw%3D%3D (Pubitemid 46089672)
38. I Durand-Zaleski 2005 Economic evaluation of radiotherapy: methods and results Cancer Radiother 9 449 451 16219481 (Pubitemid 41719058)
39. MT Groot CG Boeken Kruger RC Pelger CA Uyl-de Groot 2003 Costs of prostate cancer, metastatic to the bone, in the Netherlands Eur. Urol. 43 226 232 12600424 10.1016/S0302-2838(03)00007-1 1:STN:280:DC%2BD3s%2FovFeitQ%3D%3D (Pubitemid 36314233)
40. Curtis, L.: Unit costs of health and social care 2007. Personal Social Services Research Unit. University of Kent, Canterbury (2007)